@susonllc's Super Patch video — a disclosed ad that framed the product as "braille for the brain" — pulled tens of thousands of views at 93.6x that creator's own baseline. In a category where the majority of brands just buy paid placements, one UGC creator with a vivid hook and an FDA registration angle beat a whole market of media spend. That's the result. Now let's pull it apart.
Key takeaways
- A disclosed Super Patch UGC video hit 93.6x creator baseline — the top outlier in the niche — built on a drug-free contrast angle and symptom-specific hashtag depth.
- Super Patch runs 75% of its reach through UGC creators; One-Day TMS runs 97% UGC — both prove the channel converts in consumer neurotech at scale.
- Most rivals (14 of 31 tracked) default to paid ads, leaving the UGC lane contested but not saturated — the opening is volume and account ownership, not discovery.
- The winning content pattern is consistent: lead with a plain-language mechanism claim, stack condition-specific hashtags, and let the creator voice carry the credibility.
The brands that cracked UGC — and how
The niche has a clear paid-ads majority. But three brands — Super Patch, One-Day TMS, and Sooma — already lead on UGC creators, and their results are pulling well ahead of the ad-spend pack in creator-driven reach.
Super Patch is the most instructive case. With 75% of its reach coming from UGC creators, it has effectively built a parallel distribution engine alongside a modest paid layer. One-Day TMS goes even further: 97% of its reach is UGC-led, with almost nothing in paid. Sooma runs a similar 92% UGC split. These aren't experiments — they're the established playbook in the category, and they're pulling millions and hundreds of thousands of views respectively.
What separates them from the 14 paid-ads-led competitors — names like Muse (InteraXon), Apollo Neuroscience, Halo Neuroscience, and NeuroVIZR — isn't product quality or brand awareness. It's the decision to put real creators at the center of distribution rather than buying placement.
What the top outlier actually did
@susonllc's video is a masterclass in neurotech consumer framing. The hook — "braille for the brain" — is a plain-language analogy that makes a genuinely complex mechanism immediately tangible. From there, the caption pivots to credibility: FDA registration as a medical device. Then the contrast move: stop using #melatonin, #tylenol, #caffeine — try a non-ingredient patch instead.
That contrast structure does a lot of work. It anchors the product against familiar, well-understood alternatives, which reduces the cognitive load for a skeptical buyer. And the hashtag stack — #pain, #insomnia, #tired, #exhausted, #energy, #fibromyalgia, #autoimmune, #painrelief, #anxiety, #depression, #mood, #inflammation — isn't random. It's a condition-by-condition map of the audience's search behavior. Every tag is a door into a different symptom community. This is exactly why the video over-indexed so dramatically: it was findable by a wide band of people looking for relief across multiple overlapping conditions.
Crucially, this was a disclosed ad — #superpatch is in the tags, the partnership is visible — and it still hit 93.6x baseline. That's the strategic wrinkle worth sitting with: disclosure didn't kill performance; the mechanism framing and hashtag depth did the work regardless.
The second-highest outlier: a different brand, same principle
@neurable_ on Instagram pulled 79.1x creator baseline for Neurable — and the caption pattern echoes the same logic. The video leads with a concrete mechanism (EEG sensors in the ear pads, brainwave tracking for focus and stress), then bridges to a benefit the audience already wants: staying in the zone, managing mental state. Hashtags like #BrainTech, #SmartHeadphones, #techtips, and #techreels reach the tech-curious audience rather than a clinical one. It's a different positioning angle from Super Patch — audiophile-meets-cognitive-enhancement rather than symptom relief — but the structure is identical: plain mechanism, concrete benefit, audience-native tags.
The rest of the outlier set — the pattern holds
@flowneuroscience ran a disclosed ad (#AD, clearly marked) on Instagram featuring a Consultant Psychiatrist and UK Medical Director discussing the link between brain activity and low mood, pulling 64.3x baseline for Flow Neuroscience. Expert voice plus clinical credibility plus an open question to the audience ("what would you like to know?") — that's a participation hook layered onto a trust signal. Again: disclosed, and still massively over-indexed.
@staneciagraham took a different format for Super Patch — a detailed 20-question FAQ-style caption covering mechanism, safety, patch variants, cost, and shipping — pulling 63.1x baseline. This is bottom-of-funnel content doing top-of-funnel reach numbers. The depth itself became the differentiator.
@hancykhalid hit 62.4x baseline for BrainCo using coverage of the brand's AI-powered bionic hand at WAIC 2026, tagged into #ai, #innovation, and #waic2026. This is organic tech-news coverage doing breakout numbers — a reminder that earned credibility through event and product news still generates significant reach even in a creator context.
The repeatable playbook
Pull these outliers together and four tactics repeat:
1. Lead with the mechanism in plain language. "Braille for the brain," "QR code for your nervous system," "EEG sensors in the ear pads" — not technical jargon, not brand-speak. One concrete analogy or descriptor that makes the science tangible.
2. Use the contrast move. Position against familiar, over-used alternatives (#melatonin, #tylenol, #caffeine). This is especially effective in neurotech because the product category is still unfamiliar — anchoring to something the audience already rejects makes adoption easier.
3. Stack condition-specific hashtags, not generic wellness tags. The difference between #wellness and #fibromyalgia, #insomnia, #anxiety is the difference between broadcasting and targeting. Symptom-specific tags reach people in active problem-solving mode.
4. Disclosure doesn't cost you performance. Three of the five top outliers are disclosed ads. The framing and specificity are what drive views — transparency doesn't suppress them.
Where the opening actually is
The creator lane here is contested, not wide open. Super Patch, One-Day TMS, and Sooma have already proven UGC works at scale in this niche. The real opportunity for a challenger isn't to discover a new channel — it's to out-execute the existing UGC leaders at volume, with dedicated creator accounts the brand owns and content that runs the proven pattern more consistently and across more symptom verticals than any single creator can sustain.
The paid-ads majority (Muse, Apollo Neuroscience, Halo Neuroscience, NeuroVIZR, R3ta, and others) is buying reach but not building creator equity. That's a durable gap for any brand willing to operate creator content as a system rather than a campaign.
How 8x runs this at volume
The Super Patch playbook — mechanism hook, contrast framing, condition-specific hashtag depth, disclosed creator voice — is repeatable. But repeating it at scale requires more than briefing a handful of creators. It requires dedicated accounts, consistent content cadence, and the ability to test mechanism angles and hashtag clusters across many creators simultaneously, with the brand owning the output.
That's exactly what 8x builds: a managed UGC engine for consumer brands where the creators, the accounts, and the videos are all client-owned assets — not rented reach. If you're in consumer neurotech and watching paid-ads spend compound without building equity, see how 8x sets this up for brands like yours.
FAQ
What made @susonllc's Super Patch video hit 93x creator baseline as a disclosed ad?
The video led with a plain-language mechanism hook ('braille for the brain'), anchored the product against familiar alternatives like melatonin and caffeine, and stacked condition-specific hashtags across pain, sleep, mood, and autoimmune communities — making it findable by a wide, high-intent audience. Disclosure via #superpatch didn't suppress performance; the framing and hashtag depth did the work.
How does Super Patch generate millions in reach without relying mainly on paid ads?
Super Patch routes roughly 75% of its reach through UGC creators — a dedicated creator base producing content across multiple symptom verticals. One-Day TMS and Sooma run similar UGC-dominant splits (97% and 92% respectively), showing this isn't an anomaly but a proven distribution model in consumer neurotech.
What content format wins in the consumer neurotech wearables niche?
The breakout pattern across the top outliers is: a concrete mechanism explained in plain language, a contrast move against over-used alternatives, symptom-specific hashtag stacks rather than generic wellness tags, and a creator voice — disclosed or not — that carries credibility. FAQ-depth captions and expert-guest formats also over-index versus short promotional copy.
Is the UGC creator lane in consumer neurotech already taken, or is there still room to compete?
It's contested, not closed. Super Patch, One-Day TMS, and Sooma have already proven UGC at scale, but the majority of the category (14 of 31 tracked brands) still defaults to paid ads. The opportunity is to out-execute existing UGC leaders at volume — more creators, more symptom verticals, more owned accounts — not to discover an untapped channel.
